On Thursday, BofA Securities analyst Travis Steed reduced the price target on Embecta shares (NASDAQ: EMBC) to $18.00, down from the previous $20.00, while maintaining an Underperform rating on the ...

Embecta (Nasdaq:EMBC) today revealed its phased plan to create value and shift priorities toward broader medical applications. The pure-play diabetes technology company has endured ups and downs since ...